{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Obstetrical and Gynecological Survey - Vol. 77, No. 10
Activity Steps
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Description
Method of Participation in the Learning Process/Evaluation Method Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form. Getting the Most out of the Activity As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed. While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.Learning Objectives
After completing this continuing education activity you will be able to:
- CME Article 22: Effect of Intrapartum Maternal Hemoglobin on Mode of Delivery and Short-Term Neonatal Outcome: A Systematic Review -- Describe how Hb levels affect mode of delivery and short-term neonatal outcome, and identify abnormal Hb levels and propose appropriate treatment and monitoring recommendations.
- CME Article 23: Guidelines for Cystic Fibrosis Carrier Screening in the Prenatal/Preconception Period -- Define indications and the current guidelines for carrier testing for CF; compare types of CF carrier screening and describe potential results of the screening; propose patient counseling strategies regarding residual risk after negative CF carrier screening; and explain appropriate referral measures for patients with positive CF carrier screening results.
- CME Article 24: Clinical Update on Uses for Mifepristone in Obstetrics and Gynecology -- Describe the history of the development of mifepristone, including its mechanism of action and safety profile; and explain the uses for mifepristone in both obstetrics and gynecology.
Disclosures
All authors, faculty, and staff have no relevant financial relationships with any ineligible organizations regarding this educational activity. Off-Label Usage Regarding Article 24: Drs. Jill M. Hagey and Amy G. Bryant have disclosed that the U.S. Food and Drug Administration has not approved the use of any drugs or devices for the treatment of early pregnancy loss, intrauterine fetal demise, ectopic pregnancy, pregnancy prevention, abnormal uterine bleeding, or gynecologic cancers as discussed in this article. Please consult the product?s labeling for approved information.
Price:
$30.00
Credits:
- ACCME 3.0 CME
Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 3.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
{{ evaluation.question.text }}
{{choice.text}}
{{evaluation.answerSet[0].text}}
Professions:
Physician
Test Code: OGS1022
Published: October 2022
Expires: 9/30/2024
Sources:
Obstetrical & Gynecological Survey
Required Passing Score: 10/13 (76%)
Categories:
Gynecological
,
Obstetrical
Specialties:
Gynecology,
OB/GYN